diagnosis

Aplastic Anemia and Non-Transplant Therapies

Thumbnail for video Watch Now

Topic(s)
Aplastic Anemia
Presenter(s)
Taha Bat, MD
Patients may learn about a variety of treatments for aplastic anemia. Sometimes the preference will be a non-transplant treatment. This webinar, which includes questions from the live audience at the end, describes the types of treatments and why each may be considered.

Ask the Pediatric Expert

Thumbnail for video Watch Now

Topic(s)
Pediatric Bone Marrow Failure Diseases
Presenter(s)
Joseph Oved, MD
Dr. Joseph Oved answers questions from participants. The webinar covers most of the most pressing questions from parents about the disease and treatment of their child with bone marrow failure disease.

When Does a PNH Clone Have Clinical Significance?

Thumbnail for video Watch Now

Topic(s)
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Daria Babushok, MD, PhD
Dr. Daria Babushok discusses the significance of PNH clones in the diagnostic assessment of patients with bone marrow failure and recognized indications for starting complement inhibitor therapy in PNH (Paroxysmal Nocturnal Hemoglobinuria). The question and answer session is…

VEXAS Syndrome

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
David Beck, MD, PhD
In this webinar, Dr. David Beck, MD, PhD and Anna Cantor, MA, MS, CGC, discuss VEXAS syndrome which is a newly discovered auto-inflammatory condition affecting older adults. VEXAS syndrome often overlaps with myelodysplastic syndromes (MDS) with autoimmune disorders (AD). The…

David Beck, MD, PhD

Institution
NYU Grossman School of Medicine
Physician Status
accepting new patients
About
My research focuses on identifying the genetic causes of human diseases as a means to both better diagnosis and treat patients and understand basic biologic principles. We are interested in studying autoimmune and auto-inflammatory diseases to elucidate the mechanism underlying these diseases and improve patient care. We use a combination of genetic, and biochemical approaches in patient derived and animal models to better understand these diseases. Our aim is to directly connect human diseases with basic innate immune biology using genetics.

Suresh Balasubramanian

Institution
Karmanos Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in the development of novel therapeutics. He strongly believes in the concept of being a physician-scientist. He completed a year of clinical research fellowship in Neuro-Oncology at Cleveland Clinic, where he investigated the role of EGFR mutations and ALK rearrangement in

Catherine J. Lee, MD

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials. Furthermore, she leads the Chronic Graft-versus-Host Disease/Long-Term Follow-Up Program for patients who have received hematopoietic cell transplantation or other immune

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.